Subjektives Befinden und Arbeitsfähigkeit nach SARS-CoV-2-Immunisierung mit dem Vektor-Impfstoff ChAdOx1-S (AstraZeneca COVID-19–Vakzin): Ergebnisse einer anonymen Umfrage

BACKGROUND: The SARS coronavirus 19 vaccine ChAdOx1‑S (Vaxzevria, AstraZeneca) has been licensed since January 2021 by the Paul Ehrlich Institute for Germany. In several campaigns, healthcare workers and medical students were offered this vaccine on a voluntary basis. AIM: The primary endpoint of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalbhenn, Johannes, Gabler, Feline, Heinrich, Sebastian, Steinmann, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Originalien
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572530/
https://www.ncbi.nlm.nih.gov/pubmed/34776649
http://dx.doi.org/10.1007/s40664-021-00448-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572530/
https://www.ncbi.nlm.nih.gov/pubmed/34776649
http://dx.doi.org/10.1007/s40664-021-00448-4

Ejemplares similares